PacliALL（白蛋白结合型紫杉醇）
Pacliall注射液
Pacliall
万能的生物技术
PROTIEN结合型紫杉醇
Panacea Biotec to unveil generic breast cancer drug PacliALL
PBR Staff Writer
Panacea Biotec, an India-based biotechnology firm, is set to introduce its indigenously developed albumin bound paclitaxel particles formulation based breast cancer treatment medicine PacliALL.
Developed at Global Research and Development (GRAND) Center in Navi Mumbai, PacliALL offers shorter infusion time and elimination of need of premedication for the patients, Panacea Biotec said.
According to the company, PacliALL will be made available at a price which will be nearly 50% lower than the competitive products in the domestic and global markets.
In a statement Panacea Biotec said PacliALL offers the advantage of improved safety over conventional formulations of Paclitaxel and is meant to be used as a chemotherapeutic agent for the treatment of breast cancer.
Panacea Biotec joint managing director Rajesh Jain said the company will remain committed to its mission of providing the latest and most affordable preventive and therapeutic care to people across the globe.
"The launch of PacliALL reflects the hardwork of Panacea Biotec''s scientists, who worked tenaciously for the development of this drug," Jain said.